Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone.
The aim of this study was to evaluate long-term weight gain associated with clozapine, olanzapine, and risperidone treatment and its clinical risk factors in children and adolescents. At four child and adolescent psychiatric departments, the weight and body mass index of initially hospitalized patients (aged 9.0-21.3 years) treated with clozapine (n = 15), olanzapine (n = 8), and risperidone (n = 10) were prospectively monitored for 45 weeks. Clinical risk factors (age, gender, baseline weight, dosage, drug-naivety) were tested for their association with weight gain in the three groups. All three groups experienced significant weight gain between baseline and endpoint. The absolute and percentage average weight gains were significantly higher for the olanzapine group (16.2 +/- 8.8 kg; 30.1 +/- 18.9%) than for the clozapine (9.5 +/- 10.4 kg; 14.8 +/- 15.8%) and the risperidone (7.2 +/- 5.3 kg; 11.5 +/- 6.0%) groups. Olanzapine is associated with extreme long-term weight gain in children and adolescents that, in addition, is much higher than that expected in adults. Clozapine and risperidone are associated with a less marked weight gain in children and adolescents but also much higher than that expected in adults. These differences may affect compliance with medication and health risk.
Fleischhaker
Christian
C
Department of Child and Adolescent Psychiatry and Psychotherapy, University of Freiburg, Hauptstrasse 8, 79104, Freiburg, Germany. christian.fleischhaker@uniklinik-freiburg.de
Heiser
Philip
P
Hennighausen
Klaus
K
Herpertz-Dahlmann
Beate
B
Holtkamp
Kristian
K
Mehler-Wex
Claudia
C
Rauh
Reinhold
R
Remschmidt
Helmut
H
Schulz
Eberhard
E
Warnke
Andreas
A
D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D015992:Body Mass Index; D002648:Child; D003024:Clozapine / Q000009:adverse effects*; D005260:Female; D006778:Hospitals, Psychiatric; D006801:Humans; D007297:Inpatients; D008297:Male; D000077152:Olanzapine; D018408:Patch-Clamp Techniques; D012307:Risk Factors; D018967:Risperidone / Q000009:adverse effects*; D015430:Weight Gain / Q000187:drug effects*; D055815:Young Adult
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003024:Clozapine; D018967:Risperidone; D000077152:Olanzapine
J Clin Psychopharmacol. 1999 Feb;19(1):37-44
9934941
Am J Psychiatry. 1999 Aug;156(8):1170-6
10450256
J Child Adolesc Psychopharmacol. 2003 Fall;13(3):301-9
14642018
Am J Psychiatry. 1999 Nov;156(11):1686-96
10553730
South Med J. 1983 Nov;76(11):1407-12
6138860
J Am Acad Child Adolesc Psychiatry. 1997 May;36(5):685-93
9136504
J Child Adolesc Psychopharmacol. 2000 Summer;10(2):79-90
10933118
Am J Psychiatry. 1994 Jun;151(6):825-35
7514366
J Am Acad Child Adolesc Psychiatry. 1995 Sep;34(9):1147-52
7559308
J Am Acad Child Adolesc Psychiatry. 2002 Mar;41(3):337-43
11886029
J Child Adolesc Psychopharmacol. 2000 Summer;10(2):69-78
10933117
Neuropsychopharmacology. 2004 Jan;29(1):133-45
14583740
J Child Adolesc Psychopharmacol. 1998;8(3):151-9
9853689
Fortschr Neurol Psychiatr. 1995 May;63(5):173-93
7782019
Compr Psychiatry. 1996 Jan-Feb;37(1):68-73
8770530
J Am Acad Child Adolesc Psychiatry. 1999 Aug;38(8):960-5
10434487
Neurosci Biobehav Rev. 1995 Winter;19(4):533-52
8684715
Ann Intern Med. 1993 Oct 1;119(7 Pt 2):655-60
8363192
N Engl J Med. 2002 Aug 1;347(5):314-21
12151468
J Child Adolesc Psychopharmacol. 2002 Winter;12(4):337-45
12625994
Pediatr Diabetes. 2008 Jun;9(3 Pt 2):23-32
18540866
J Am Acad Child Adolesc Psychiatry. 1998 Apr;37(4):372-6
9549957
J Clin Psychiatry. 1999 Jun;60(6):358-63
10401912
J Clin Psychiatry. 2001 Apr;62(4):239-48
11379837
J Neural Transm (Vienna). 2003 May;110(5):545-60
12721815
Am J Psychiatry. 2004 Aug;161(8):1334-49
15285957
J Am Acad Child Adolesc Psychiatry. 1994 Jun;33(5):658-63
8056728
J Clin Psychiatry. 2004;65 Suppl 18:13-26
15600381
J Child Adolesc Psychopharmacol. 1997;7(3):167-79
9466234
J Child Adolesc Psychopharmacol. 1998;8(1):49-59
9639079
J Am Acad Child Adolesc Psychiatry. 1998 Apr;37(4):377-85
9549958
J Clin Psychiatry. 2002 Oct;63(10):856-65
12416594
Am J Psychiatry. 1992 Jan;149(1):68-72
1728188
J Child Adolesc Psychopharmacol. 2000 Winter;10(4):259-68
11191686
J Autism Dev Disord. 1997 Jun;27(3):313-23
9229261
Eur Child Adolesc Psychiatry. 2002 Jun;11(3):129-33
12369772
J Clin Psychiatry. 2001;62 Suppl 7:22-31
11346192
Am J Psychiatry. 2002 Aug;159(8):1337-46
12153826
J Am Acad Child Adolesc Psychiatry. 2000 Apr;39(4):509-16
10761354
J Child Adolesc Psychopharmacol. 2003 Fall;13(3):311-7
14642019
J Am Acad Child Adolesc Psychiatry. 1999 Nov;38(11):1327-8
10560215
J Child Adolesc Psychopharmacol. 2001 Fall;11(3):229-38
11642473
J Clin Psychiatry. 1997;58 Suppl 10:45-9
9265916
South Med J. 1989 May;82(5):611-7
2566204
J Child Adolesc Psychopharmacol. 2006 Jun;16(3):308-16
16768638
J Am Acad Child Adolesc Psychiatry. 2003 Feb;42(2):170-5
12544176
J Child Adolesc Psychopharmacol. 2001 Fall;11(3):239-50
11642474
J Neural Transm (Vienna). 2007 Feb;114(2):273-80
17109073
Am J Psychiatry. 1996 Jun;153(6):817-9
8633697
J Child Adolesc Psychopharmacol. 1999;9(2):93-8
10461819
J Am Acad Child Adolesc Psychiatry. 2001 Oct;40(10):1206-14
11589534
J Child Adolesc Psychopharmacol. 2001 Spring;11(1):5-13
11322745
J Child Adolesc Psychopharmacol. 2003 Fall;13(3):319-27
14642020
Arch Gen Psychiatry. 2006 Jul;63(7):721-30
16818861
J Child Adolesc Psychopharmacol. 2000 Spring;10(1):19-26
10755578
J Child Adolesc Psychopharmacol. 2008 Feb;18(1):54-69
18294089
J Am Acad Child Adolesc Psychiatry. 1997 May;36(5):694-700
9136505
J Child Adolesc Psychopharmacol. 1998;8(2):107-13
9730076
Am J Psychiatry. 2002 Jun;159(6):1055-7
12042200
Arch Gen Psychiatry. 1996 Dec;53(12):1090-7
8956674